Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation

Dipeptidyl peptidase-4 (DPP-4) inhibitors are used for the treatment of type 2 diabetes mellitus (DM). Recent studies have shown that beyond their effect in lowing glucose, DPP-4 inhibitors mitigate DM-related microvascular complications, such as diabetic retinopathy. However, the mechanism by which...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Songyi, Kim, Mi-Kyung, Kim, Ryul-I, Yeo, Yeongju, Kim, Koung Li, Suh, Wonhee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080693/
https://www.ncbi.nlm.nih.gov/pubmed/33051573
http://dx.doi.org/10.1038/s12276-020-00512-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080693/
https://www.ncbi.nlm.nih.gov/pubmed/33051573
http://dx.doi.org/10.1038/s12276-020-00512-8

Ejemplares similares